Tachykinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  • Jeffrey Barrett Children's Hospital of Philadelphia
  • Brenden Canning Johns Hopkins
  • Joseph Coulson University of Edinburgh
  • Erin Dombrowsky Children's Hospital of Philadelphia
  • Steven D. Douglas University of Pennsylvania
  • Tung M. Fong Covance Inc
  • Christa Y. Heyward Children's Hospital of Philadelphia
  • Susan E. Leeman Boston University
  • Pranela Remeshwar University of Medicine and Dentistry of New Jersey


Tachykinin receptors (provisional nomenclature as recommended by NC-IUPHAR [90]) are activated by the endogenous peptides substance P (SP), neurokinin A (NKA; previously known as substance K, neurokinin α, neuromedin L), neurokinin B (NKB; previously known as neurokinin β, neuromedin K), neuropeptide K and neuropeptide γ (N-terminally extended forms of neurokinin A). The neurokinins (A and B) are mammalian members of the tachykinin family, which includes peptides of mammalian and nonmammalian origin containing the consensus sequence: Phe-x-Gly-Leu-Met. Marked species differences in in vitro pharmacology exist for all three receptors, in the context of nonpeptide ligands. Antagonists such as aprepitant and fosaprepitant were approved by FDA and EMA, in combination with other antiemetic agents, for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.
How to Cite
Barrett, J., Canning, B., Coulson, J., Dombrowsky, E., Douglas, S. D., Fong, T. M., Heyward, C. Y., Leeman, S. E. and Remeshwar, P. (2019) “Tachykinin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database”, IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi: 10.2218/gtopdb/F62/2019.4.